TIDMAVO
Advanced Oncotherapy PLC
11 May 2022
Reach non-regulatory announcement
11 May 2022
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Scientific publications highlight potential of LIGHT system in
effectively delivering FLASH radiotherapy
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the
next-generation proton therapy system for cancer treatment, notes
the recent publication of two papers showcasing the potential
superiority of the LIGHT system, over other existing proton therapy
systems, in the delivery of FLASH.
In the first paper titled "Ultra-high dose rate radiation
production and delivery systems intended for FLASH"(1) written by
Jonathan Farr, Chief Clinical Officer at the Company, and his
co-authors, the LIGHT system was assessed and it has been shown
that it is ideally positioned to deliver FLASH, as it is a 'pulsed
system' sending out up to 500 million protons in each burst, at 200
times per second. The number of particles per pulse has been noted
as a critical FLASH parameter for other (electron) systems, and now
it is becoming available from LIGHT for proton FLASH
treatments.
In the second paper titled "Treatment planning for FLASH
radiotherapy: General aspects and applications to proton beams"(2)
, Anna Kolano, a Medical Physicist at the Company, and her
co-authors highlight the applicability of FLASH in patient
treatment. FLASH proton therapy is currently administered
clinically with "Shoot-Through FLASH Beams", analogous to X-rays,
as legacy proton systems require thick physical beam absorbers to
achieve the lower energies required for patient treatment. However,
the LIGHT system, which produces all energies electronically, is
designed to deliver FLASH treatments anywhere in the human body.
Hence, the LIGHT FLASH plan for "Conformal Scanned FLASH Beams" is
conceptually superior to the Shoot-Through method.
Dr Jonathan Farr, Chief Clinical Officer at Advanced Oncotherapy
said:
"The results published showcase the potential superiority of the
LIGHT system for delivering FLASH radiotherapy. FLASH proton
therapy provides the potential to change clinical practice and
improve patient outcomes, as it could see patients treated in a
single session with significantly reduced normal tissue toxicity
burden post-treatment, and the Company's LIGHT system is ideally
positioned to deliver it. There is an urgent need to treat more
cancer patients while reducing the toxicity burden, which can
damage healthy tissue, associated with legacy radiation therapy
systems."
Notes
1- Farr, J, Grilj, V, Malka, V, Sudharsan, S, Schippers, M.
Ultra-High dose rate radiation production and delivery systems
intended for FLASH. Med Phys 2022; 00 1- 37.
https://doi.org/10.1002/mp.15659
2- Schwarz, M, Traneus, E, Safai, S, Kolano, A, van de Water, S.
Treatment planning for FLASH radiotherapy: General aspects and
applications to proton beams. Med Phys. 2022; 49: 2861- 2874.
https://doi.org/10.1002/mp.15579
- ENDS -
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and
Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Tel: +44 (0) 20 3328 5656
Finance)
Amrit Nahal / Matt Butlin (Sales
and Corporate Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
FTI Consulting (Financial PR & IR) advancedoncotherapy@fticonsulting.com
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
About FLASH radiotherapy
FLASH radiotherapy, in which ultra-high radiation doses, several
orders of magnitude higher than that currently used in conventional
clinical radiotherapy, are delivered in fractions of a second,
offers the potential to treat cancer patients in a single visit,
rather than up to 30 visits with conventional radiation therapy,
and has the potential to revolutionise the future of cancer
treatment.
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
About Reach announcements
This is a Reach announcement. Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute media only / non-regulatory news
releases into the public domain. Information required to be
notified under the AIM Rules for Companies, Market Abuse Regulation
or other regulation would be disseminated as an RNS regulatory
announcement and not on Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABKKBKDBKBQPD
(END) Dow Jones Newswires
May 11, 2022 02:02 ET (06:02 GMT)
Advanced Oncotherapy (LSE:AVO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Advanced Oncotherapy (LSE:AVO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
